<DOC>
	<DOCNO>NCT01026415</DOCNO>
	<brief_summary>The purpose study identify brentuximab vedotin drug-drug interaction patient CD30-positive cancer determine main route excretion . The study also assess blood drug level patient renal hepatic impairment ( special population ) .</brief_summary>
	<brief_title>Clinical Pharmacology Study Brentuximab Vedotin ( SGN-35 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Adequate organ function ( Special Populations : serum bilirubin &gt; 2 mg/dL creatinine clearance &lt; 50 mL/min ) ECOG performance status &lt; 2 ( Special Populations : &lt; 4 ) Relapsed refractory CD30positive malignancy Receiving prohibit medication within 4 week Poor liver function ( ChildPugh class C ) Current diagnosis primary cutaneous ALCL Acute chronic graftversushost disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Disease , Hodgkin</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>monomethyl auristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>